Khiron Life Sciences Reports Second Quarter Fiscal 2019 Financial Results

Advances multi-country operator strategy with acquisition of NettaGrowth, securing first medical THC and CBD cannabis license and cultivation capacity in Uruguay, and potential for access to Brazilian market Closes $28,751,035 bought deal financing, including full exercise of over-allotment option Completed the quarter with $55.8 million in cash Expands distribution for Kuida cosmeceutical brand, signing distribution agreements with Fedco, Linio, Cafam